[ Back ]   [ More News ]   [ Home ]
Protolabs Reports Financial Results for the Third Quarter of 2024

Total Revenue of $126 Million

GAAP Earnings Per Share of $0.29, Non-GAAP Earnings Per Share of $0.47

MINNEAPOLIS — (BUSINESS WIRE) — November 1, 2024 — Proto Labs, Inc. ("Protolabs" or the "Company") (NYSE: PRLB), the world’s leading provider of digital manufacturing services, today announced financial results for the third quarter ended September 30, 2024.

Third Quarter 2024 Financial Highlights:

"Our disciplined approach and resilient business model drove solid financial results in the third quarter, despite continued dynamic challenges in the manufacturing sector," said Rob Bodor, President and Chief Executive Officer. "We remain committed to accelerating our growth, as highlighted by the actions we initiated at the end of the second quarter to reorganize our internal structure and better position the company for growth and value-creation over the long-term. We are committed to executing on our priorities and increasing value for our shareholders."

Dan Schumacher, Chief Financial Officer, commented: "In the third quarter, our business generated its highest quarterly operating cash flow since 2020—before the acquisition of 3D Hubs. This is a testament to the profitability of Protolabs' model against any macro backdrop, driven by our unique combined factory and network model. We will continue to invest profits to accelerate growth and create value for shareholders."

Additional Third Quarter 2024 Highlights:

Fourth Quarter 2024 Outlook

For the fourth quarter of 2024, the Company expects to generate revenue between $115 million and $123 million.

The Company expects fourth quarter 2024 diluted net income per share between $0.10 and $0.18, and non-GAAP diluted net income per share between $0.28 and $0.36. See "Non-GAAP Financial Measures" below.

Non-GAAP Financial Measures

The Company has included non-GAAP revenue growth by region and by service line that excludes the impact of changes in foreign currency exchange rates (collectively, “non-GAAP revenue growth”). Management believes these metrics, when viewed in conjunction with the comparable GAAP metrics, are useful in evaluating the underlying business trends and ongoing operating performance of the Company.

The Company has included earnings before interest, taxes, depreciation and amortization (“EBITDA”) and EBITDA, adjusted for stock-based compensation expense, unrealized (gain) loss on foreign currency and costs related to the Japan closure activities (collectively, “Adjusted EBITDA”), in this press release to provide investors with additional information regarding the Company’s financial results. The Company has also included earnings before interest, taxes, depreciation and amortization margin (“EBITDA margin”) and EBITDA margin, adjusted for stock-based compensation expense, unrealized (gain) loss on foreign currency and costs related to the Japan closure activities (collectively, “Adjusted EBITDA margin”), in this press release to provide investors with additional information regarding the Company’s financial results.

The Company has included non-GAAP gross margin, adjusted for stock-based compensation expense and amortization expense in this press release to provide investors with additional information regarding the Company’s financial results.

The Company has included non-GAAP operating margin, adjusted for stock-based compensation expense, amortization expense and costs related to the closure of Japan (collectively, “non-GAAP operating margin”), in this press release to provide investors with additional information regarding the Company’s financial results.

The Company has included non-GAAP net income, adjusted for stock-based compensation expense, amortization expense, unrealized (gain) loss on foreign currency and costs related to the closure of Japan (collectively, “non-GAAP net income”), in this press release to provide investors with additional information regarding the Company’s financial results.

The Company has provided below reconciliations of GAAP to non-GAAP net income, non-GAAP gross margin, non-GAAP operating margin, non-GAAP revenue growth by region and by service, and Adjusted EBITDA and Adjusted EBITDA margin, the most directly comparable measures calculated and presented in accordance with GAAP. These non-GAAP measures are used by the Company’s management and board of directors to understand and evaluate operating performance and trends and provide useful measures for period-to-period comparisons of the Company’s business. Accordingly, the Company believes that these non-GAAP measures provide useful information to investors and others in understanding and evaluating operating results in the same manner as our management and board of directors.

Conference Call

The Company has scheduled a conference call to discuss its third quarter 2024 financial results and fourth quarter 2024 outlook today, November 1, 2024 at 8:30 a.m. EDT. To access the call in the U.S. please dial 877-709-8150 or outside the U.S. dial 201-689-8354 at least five minutes prior to the 8:30 a.m. EDT start time. No participant code is required. A simultaneous webcast of the call and accompanying presentation will be available via the investor relations section of the Protolabs website and the following link: https://edge.media-server.com/mmc/p/b94yu8yp/. A replay will be available for 14 days following the call on the investor relations section of the Protolabs website.

About Protolabs

Protolabs is the fastest and most comprehensive digital manufacturing service in the world. Our digital factories produce low-volume parts in days while Protolabs Network unlocks advanced capabilities and volume pricing through its highly vetted manufacturing partners. The result? One manufacturing source—from prototyping to production—for product developers, engineers, and supply chain teams across the globe. See what's next at protolabs.com.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical or current facts are “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act of 1995. These statements involve known and unknown risks, uncertainties and other factors which may cause the results of Protolabs to be materially different than those expressed or implied in such statements. Certain of these risk factors and others are described in the “Risk Factors” section within reports filed with the SEC. Other unknown or unpredictable factors also could have material adverse effects on Protolabs’ future results. The forward-looking statements included in this press release are made only as of the date hereof. Protolabs cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. Finally, Protolabs expressly disclaims any intent or obligation to update any forward-looking statements to reflect subsequent events or circumstances.

Proto Labs, Inc.

Condensed Consolidated Balance Sheets

(In thousands)

 

 

 

 

 

 

September 30,
2024

 

December 31,
2023

 

(Unaudited)

 

 

Assets

 

 

 

Current assets

 

 

 

Cash and cash equivalents

$

87,873

 

$

83,790

Short-term marketable securities

 

12,638

 

 

19,013

Accounts receivable, net

 

69,464

 

 

72,848

Inventory

 

12,415

 

 

13,657

Income taxes receivable

 

665

 

 

2,228

Prepaid expenses and other current assets

 

10,019

 

 

9,124

Total current assets

 

193,074

 

 

200,660

 

 

 

 

Property and equipment, net

 

237,942

 

 

253,655

Goodwill

 

273,991

 

 

273,991

Other intangible assets, net

 

22,890

 

 

25,584

Long-term marketable securities

 

17,120

 

 

8,019

Operating lease assets

 

3,519

 

 

4,628

Finance lease assets

 

759

 

 

960

Other long-term assets

 

4,491

 

 

4,856

Total assets

$

753,786

 

$

772,353

 

 

 

 

Liabilities and shareholders' equity

 

 

 

Current liabilities

 

 

 

Accounts payable

$

15,004

 

$

15,636

Accrued compensation

 

17,549

 

 

15,292

Accrued liabilities and other

 

18,455

 

 

16,872

Current operating lease liabilities

 

1,450

 

 

1,585

Current finance lease liabilities

 

306

 

 

296

Income taxes payable

 

994

 

 

Total current liabilities

 

53,758

 

 

49,681

 

 

 

 

Long-term operating lease liabilities

 

1,979

 

 

3,008

Long-term finance lease liabilities

 

365

 

 

595

Long-term deferred tax liabilities

 

12,688

 

 

18,742

Other long-term liabilities

 

5,003

 

 

5,032

 

 

 

 

Shareholders' equity

 

679,993

 

 

695,295

Total liabilities and shareholders' equity

$

753,786

 

$

772,353

 

 

 

 

 

 

 

 

Proto Labs, Inc.

Condensed Consolidated Statements of Operations

(In thousands, except share and per share amounts)

(Unaudited)

 

 

 

 

 

 

 

 

 

 

Three Months Ended
September 30,

 

Nine Months Ended
September 30,

 

2024

 

2023

 

2024

 

2023

Revenue

 

 

 

 

 

 

 

Injection Molding

$

46,831

 

$

51,688

 

$

148,574

 

$

152,455

 

CNC Machining

 

53,327

 

 

52,916

 

 

154,498

 

 

149,317

 

3D Printing

 

21,437

 

 

21,622

 

 

64,300

 

 

63,952

 

Sheet Metal

 

3,743

 

 

4,291

 

 

11,218

 

 

12,478

 

Other Revenue

 

281

 

 

188

 

 

550

 

 

627

 

Total Revenue

 

125,619

 

 

130,705

 

 

379,140

 

 

378,829

 

 

 

 

 

 

 

 

 

Cost of revenue

 

68,389

 

 

71,423

 

 

207,897

 

 

212,648

 

Gross profit

 

57,230

 

 

59,282

 

 

171,243

 

 

166,181

 

 

 

 

 

 

 

 

 

Operating expenses

 

 

 

 

 

 

 

Marketing and sales

 

22,619

 

 

21,682

 

 

69,070

 

 

65,863

 

Research and development

 

9,772

 

 

10,105

 

 

31,600

 

 

30,647

 

General and administrative

 

16,259

 

 

17,058

 

 

49,167

 

 

49,713

 

Closure of Japan business

 

 

 

22

 

 

 

 

186

 

Total operating expenses

 

48,650

 

 

48,867

 

 

149,837

 

 

146,409

 

Income from operations

 

8,580

 

 

10,415

 

 

21,406

 

 

19,772

 

Other income (loss), net

 

1,288

 

 

320

 

 

3,548

 

 

(1,758

)

Income before income taxes

 

9,868

 

 

10,735

 

 

24,954

 

 

18,014

 

Provision for income taxes

 

2,679

 

 

2,781

 

 

7,957

 

 

7,784

 

Net income

$

7,189

 

$

7,954

 

$

16,997

 

$

10,230

 

 

 

 

 

 

 

 

 

Net income per share:

 

 

 

 

 

 

 

Basic

$

0.29

 

$

0.31

 

$

0.67

 

$

0.39

 

Diluted

$

0.29

 

$

0.31

 

$

0.67

 

$

0.39

 

 

 

 

 

 

 

 

 

Shares used to compute net income per share:

 

 

 

 

 

 

 

Basic

 

24,980,536

 

 

26,023,830

 

 

25,304,985

 

 

26,296,304

 

Diluted

 

25,022,485

 

 

26,028,456

 

 

25,382,280

 

 

26,327,606

 

 

 

 

 

 

 

 

 

Proto Labs, Inc.

Condensed Consolidated Statements of Cash Flows

(In thousands)

(Unaudited)

 

 

 

 

 

 

Nine Months Ended
September 30,

 

 

2024

 

 

 

2023

 

Operating activities

 

 

 

Net income

$

16,997

 

 

$

10,230

 

Adjustments to reconcile net income to net cash provided by operating activities:

 

 

 

Depreciation and amortization

 

26,984

 

 

 

28,213

 

Stock-based compensation expense

 

12,716

 

 

 

11,811

 

Deferred taxes

 

(6,140

)

 

 

(9,197

)

Interest on finance lease obligations

 

26

 

 

 

859

 

Loss on impairment of equipment

 

256

 

 

 

 

Loss on foreign currency translation

 

 

 

 

3,906

 

Gain on disposal of property and equipment

 

(24

)

 

 

(498

)

Other

 

103

 

 

 

122

 

Changes in operating assets and liabilities

 

9,617

 

 

 

10,600

 

Net cash provided by operating activities

 

60,535

 

 

 

56,046

 

 

 

 

 

Investing activities

 

 

 

Purchases of property, equipment and other capital assets

 

(8,339

)

 

 

(9,935

)

Proceeds from sales of property, equipment and other capital assets

 

34

 

 

 

693

 

Purchases of marketable securities

 

(18,087

)

 

 

 

Proceeds from call redemptions and maturities of marketable securities

 

15,709

 

 

 

19,115

 

Net cash (used in) provided by investing activities

 

(10,683

)

 

 

9,873

 

 

 

 

 

Financing activities

 

 

 

Proceeds from exercises of stock options and employee stock purchases

 

2,094

 

 

 

1,986

 

Purchases of shares withheld for tax obligations

 

(1,920

)

 

 

(1,436

)

Repurchases of common stock

 

(45,958

)

 

 

(39,053

)

Principal repayments of finance lease obligations

 

(220

)

 

 

(234

)

Net cash used in financing activities

 

(46,004

)

 

 

(38,737

)

Effect of exchange rate changes on cash and cash equivalents

 

235

 

 

 

(244

)

Net increase in cash and cash equivalents

 

4,083

 

 

 

26,938

 

Cash and cash equivalents, beginning of period

 

83,790

 

 

 

56,558

 

Cash and cash equivalents, end of period

$

87,873

 

 

$

83,496

 

 

 

 

 

Proto Labs, Inc.

Reconciliation of GAAP to Non-GAAP Net Income per Share

(In thousands, except share and per share amounts)

(Unaudited)

 

 

 

 

 

 

 

 

 

 

Three Months Ended
September 30,

 

Nine Months Ended
September 30,

 

 

2024

 

 

 

2023

 

 

 

2024

 

 

 

2023

 

Non-GAAP net income, adjusted for stock-based compensation expense, amortization expense, unrealized (gain) loss on foreign currency and costs related to Japan closure activities

 

 

 

 

 

 

 

GAAP net income

$

7,189

 

 

$

7,954

 

 

$

16,997

 

 

$

10,230

 

Add back:

 

 

 

 

 

 

 

Stock-based compensation expense

 

4,196

 

 

 

4,441

 

 

 

12,716

 

 

 

11,811

 

Amortization expense

 

888

 

 

 

1,461

 

 

 

2,796

 

 

 

4,471

 

Unrealized (gain) loss on foreign currency

 

174

 

 

 

(29

)

 

 

323

 

 

 

86

 

Costs related to Japan closure activities

 

 

 

 

22

 

 

 

 

 

 

4,093

 

Total adjustments 1

 

5,258

 

 

 

5,895

 

 

 

15,835

 

 

 

20,461

 

Income tax benefits on adjustments 2

 

(627

)

 

 

(633

)

 

 

(1,066

)

 

 

(931

)

Non-GAAP net income

$

11,820

 

 

$

13,216

 

 

$

31,766

 

 

$

29,760

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Non-GAAP net income per share:

 

 

 

 

 

 

 

Basic

$

0.47

 

 

$

0.51

 

 

$

1.26

 

 

$

1.13

 

Diluted

$

0.47

 

 

$

0.51

 

 

$

1.25

 

 

$

1.13

 

 

 

 

 

 

 

 

 

Shares used to compute non-GAAP net income per share:

 

 

 

 

 

 

 

Basic

 

24,980,536

 

 

 

26,023,830

 

 

 

25,304,985

 

 

 

26,296,304

 

Diluted

 

25,022,485

 

 

 

26,028,456

 

 

 

25,382,280

 

 

 

26,327,606

 

 

 

 

 

 

 

 

 

1

Stock-based compensation expense, amortization expense, unrealized (gain) loss on foreign currency and costs related to Japan closure activities were included in the following GAAP consolidated statement of operations categories:

 

Three Months Ended
September 30,

 

Nine Months Ended
September 30,

 

2024

 

2023

 

2024

 

2023

 

 

 

 

 

 

 

 

Cost of revenue

$

817

 

$

805

 

 

$

2,428

 

$

2,416

 

 

 

 

 

 

 

 

Marketing and sales

 

727

 

 

961

 

 

 

2,378

 

 

2,508

Research and development

 

671

 

 

675

 

 

 

2,031

 

 

1,888

General and administrative

 

2,869

 

 

3,461

 

 

 

8,675

 

 

9,471

Closure of Japan business

 

 

 

22

 

 

 

 

 

186

Total operating expenses

 

4,267

 

 

5,119

 

 

 

13,084

 

 

14,053

 

 

 

 

 

 

 

 

Other income (loss), net

 

174

 

 

(29

)

 

 

323

 

 

3,992

Total adjustments

$

5,258

 

$

5,895

 

 

$

15,835

 

$

20,461

 

 

 

 

 

 

 

 

2

For the three and nine months ended September 30, 2024 and 2023, income tax effects were calculated using the effective tax rate for the relevant jurisdictions. The Company's non-GAAP tax rates differ from its GAAP tax rates due primarily to the mix of activity incurred in domestic and foreign tax jurisdictions and removing effective tax rate benefits from stock-based compensation activity in the quarter.

Proto Labs, Inc.

Reconciliation of GAAP to Non-GAAP Gross Margin

(In thousands)

(Unaudited)

 

 

 

 

 

 

 

 

 

 

Three Months Ended
September 30,

 

Nine Months Ended
September 30,

 

 

2024

 

 

 

2023

 

 

 

2024

 

 

 

2023

 

Revenue

$

125,619

 

 

$

130,705

 

 

$

379,140

 

 

$

378,829

 

Gross profit

 

57,230

 

 

 

59,282

 

 

 

171,243

 

 

 

166,181

 

GAAP gross margin

 

45.6

%

 

 

45.4

%

 

 

45.2

%

 

 

43.9

%

Add back:

 

 

 

 

 

 

 

Stock-based compensation expense

 

474

 

 

 

462

 

 

 

1,401

 

 

 

1,388

 

Amortization expense

 

343

 

 

 

343

 

 

 

1,027

 

 

 

1,028

 

Total adjustments

 

817

 

 

 

805

 

 

 

2,428

 

 

 

2,416

 

Non-GAAP gross profit

$

58,047

 

 

$

60,087

 

 

$

173,671

 

 

$

168,597

 

Non-GAAP gross margin

 

46.2

%

 

 

46.0

%

 

 

45.8

%

 

 

44.5

%

 

 

 

 

 

 

 

 

Proto Labs, Inc.

Reconciliation of GAAP to Non-GAAP Operating Margin

(In thousands)

(Unaudited)

 

 

 

 

 

 

 

 

 

 

Three Months Ended
September 30,

 

Nine Months Ended
September 30,

 

 

2024

 

 

 

2023

 

 

 

2024

 

 

 

2023

 

Revenue

$

125,619

 

 

$

130,705

 

 

$

379,140

 

 

$

378,829

 

Income from operations

 

8,580

 

 

 

10,415

 

 

 

21,406

 

 

 

19,772

 

GAAP operating margin

 

6.8

%

 

 

8.0

%

 

 

5.6

%

 

 

5.2

%

Add back:

 

 

 

 

 

 

 

Stock-based compensation expense

 

4,196

 

 

 

4,441

 

 

 

12,716

 

 

 

11,811

 

Amortization expense

 

888

 

 

 

1,461

 

 

 

2,796

 

 

 

4,471

 

Costs related to Japan closure activities

 

 

 

 

22

 

 

 

 

 

 

186

 

Total adjustments

 

5,084

 

 

 

5,924

 

 

 

15,512

 

 

 

16,468

 

Non-GAAP income from operations

$

13,664

 

 

$

16,339

 

 

$

36,918

 

 

$

36,240

 

Non-GAAP operating margin

 

10.9

%

 

 

12.5

%

 

 

9.7

%

 

 

9.6

%

 

 

 

 

 

 

 

 

Proto Labs, Inc.

Reconciliation of GAAP Net Income to EBITDA and Adjusted EBITDA

(In thousands)

(Unaudited)

 

 

 

 

 

 

 

 

 

 

Three Months Ended
September 30,

 

Nine Months Ended
September 30,

 

 

2024

 

 

 

2023

 

 

 

2024

 

 

 

2023

 

Revenue

$

125,619

 

 

$

130,705

 

 

$

379,140

 

 

$

378,829

 

GAAP net income

 

7,189

 

 

 

7,954

 

 

 

16,997

 

 

 

10,230

 

GAAP net income margin

 

5.7

%

 

 

6.1

%

 

 

4.5

%

 

 

2.7

%

Add back:

 

 

 

 

 

 

 

Amortization expense

$

888

 

 

$

1,461

 

 

$

2,796

 

 

$

4,471

 

Depreciation expense

 

8,021

 

 

 

7,869

 

 

 

24,188

 

 

 

23,742

 

Interest income, net

 

(1,287

)

 

 

(561

)

 

 

(3,548

)

 

 

(1,283

)

Provision for income taxes

 

2,679

 

 

 

2,781

 

 

 

7,957

 

 

 

7,784

 

EBITDA

 

17,490

 

 

 

19,504

 

 

 

48,390

 

 

 

44,944

 

EBITDA Margin

 

13.9

%

 

 

14.9

%

 

 

12.8

%

 

 

11.9

%

Add back:

 

 

 

 

 

 

 

Stock-based compensation expense

 

4,196

 

 

 

4,441

 

 

 

12,716

 

 

 

11,811

 

Unrealized (gain) loss on foreign currency

 

174

 

 

 

(29

)

 

 

323

 

 

 

86

 

Costs related to Japan closure activities

 

 

 

 

22

 

 

 

 

 

 

4,093

 

Total adjustments

 

4,370

 

 

 

4,434

 

 

 

13,039

 

 

 

15,990

 

Adjusted EBITDA

$

21,860

 

 

$

23,938

 

 

$

61,429

 

 

$

60,934

 

Adjusted EBITDA Margin

 

17.4

%

 

 

18.3

%

 

 

16.2

%

 

 

16.1

%

 

 

 

 

 

 

 

 

Proto Labs, Inc.

Comparison of GAAP to Non-GAAP Revenue Growth by Region

(In thousands)

(Unaudited)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended
September 30, 2024

 

Three Months Ended
September 30, 2023

 

%

Change2

 

% Change

Organic3

 

GAAP

 

Foreign

Currency1

 

Non-GAAP

 

GAAP

 

 

Revenues

 

 

 

 

 

 

 

 

 

 

 

United States

$

99,571

 

$

 

 

$

99,571

 

$

103,940

 

(4.2

%)

 

(4.2

%)

Europe

 

26,048

 

 

(474

)

 

 

25,574

 

 

26,765

 

(2.7

%)

 

(4.4

%)

Total revenue

$

125,619

 

$

(474

)

 

$

125,145

 

$

130,705

 

(3.9

%)

 

(4.3

%)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Nine Months Ended
September 30, 2024

 

Nine Months Ended
September 30, 2023

 

%

Change2

 

% Change

Organic3

 

GAAP

 

Foreign

Currency1

 

Non-GAAP

 

GAAP

 

 

Revenues

 

 

 

 

 

 

 

 

 

 

 

United States

$

299,593

 

$

 

 

$

299,593

 

$

298,007

 

0.5

%

 

0.5

%

Europe

 

79,547

 

 

(1,357

)

 

 

78,190

 

 

80,822

 

(1.6

%)

 

(3.3

%)

Total revenue

$

379,140

 

$

(1,357

)

 

$

377,783

 

$

378,829

 

0.1

%

 

(0.3

%)

 

 

 

 

 

 

 

 

 

 

 

 

1

Revenue for the three and nine months ended September 30, 2024 has been recalculated using 2023 foreign currency exchange rates in effect during comparable periods to provide information useful in evaluating the underlying business trends excluding the impact of changes in foreign currency exchange rates.

2

This column presents the percentage change from GAAP revenue for the three and nine months ended September 30, 2023 to GAAP revenue for the three and nine months ended September 30, 2024.

3

This column presents the percentage change from GAAP revenue for the three and nine months ended September 30, 2023 to non-GAAP revenue for the three and nine months ended September 30, 2024 (as recalculated using the foreign currency exchange rates in effect during the three and nine months ended September 30, 2023) in order to provide a constant-currency comparison.

Proto Labs, Inc.

Comparison of GAAP to Non-GAAP Revenue Growth by Service Line

(In thousands)

(Unaudited)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended
September 30, 2024

 

Three Months Ended
September 30, 2023

 

%

Change2

 

% Change

Organic3

 

GAAP

 

Foreign

Currency1

 

Non-GAAP

 

GAAP

 

 

Revenues

 

 

 

 

 

 

 

 

 

 

 

Injection Molding

$

46,831

 

$

(198

)

 

$

46,633

 

$

51,688

 

(9.4

)%

 

(9.8

)%

CNC Machining

 

53,327

 

 

(160

)

 

 

53,167

 

 

52,916

 

0.8

 

 

0.5

 

3D Printing

 

21,437

 

 

(108

)

 

 

21,329

 

 

21,622

 

(0.9

)

 

(1.4

)

Sheet Metal

 

3,743

 

 

(4

)

 

 

3,739

 

 

4,291

 

(12.8

)

 

(12.9

)

Other Revenue

 

281

 

 

(4

)

 

 

277

 

 

188

 

49.5

 

 

47.3

 

Total Revenue

$

125,619

 

$

(474

)

 

$

125,145

 

$

130,705

 

(3.9

%)

 

(4.3

%)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Nine Months Ended
September 30, 2024

 

Nine Months Ended
September 30, 2023

 

%

Change2

 

% Change

Organic3

 

GAAP

 

Foreign

Currency1

 

Non-GAAP

 

GAAP

 

 

Revenues

 

 

 

 

 

 

 

 

 

 

 

Injection Molding

$

148,574

 

$

(666

)

 

$

147,908

 

$

152,455

 

(2.5

)%

 

(3.0

)%

CNC Machining

 

154,498

 

 

(378

)

 

 

154,120

 

 

149,317

 

3.5

 

 

3.2

 

3D Printing

 

64,300

 

 

(315

)

 

 

63,985

 

 

63,952

 

0.5

 

 

0.1

 

Sheet Metal

 

11,218

 

 

9

 

 

 

11,227

 

 

12,478

 

(10.1

)

 

(10.0

)

Other Revenue

 

550

 

 

(7

)

 

 

543

 

 

627

 

(12.3

)

 

(13.4

)

Total Revenue

$

379,140

 

$

(1,357

)

 

$

377,783

 

$

378,829

 

0.1

%

 

(0.3

%)

 

 

 

 

 

 

 

 

 

 

 

 

1

Revenue for the three and nine months ended September 30, 2024 has been recalculated using 2023 foreign currency exchange rates in effect during comparable periods to provide information useful in evaluating the underlying business trends excluding the impact of changes in foreign currency exchange rates.

2

This column presents the percentage change from GAAP revenue for the three and nine months ended September 30, 2023 to GAAP revenue for the three and nine months ended September 30, 2024.

3

This column presents the percentage change from GAAP revenue for the three and nine months ended September 30, 2023 to non-GAAP revenue for the three and nine months ended September 30, 2024 (as recalculated using the foreign currency exchange rates in effect during the three and nine months ended September 30, 2023) in order to provide a constant-currency comparison.

Proto Labs, Inc.

Customer Contact Information

(Unaudited)

 

 

 

 

 

 

 

 

 

 

Three Months Ended
September 30,

 

Nine Months Ended
September 30,

 

2024

 

2023

 

2024

 

2023

Customer contacts

 

22,511

 

 

23,080

 

 

43,671

 

 

45,668

Revenue per customer contact

$

5,580

 

$

5,663

 

$

8,682

 

$

8,295

 

 

 

 

 

 

 

 

Proto Labs, Inc.

Reconciliation of GAAP to Non-GAAP Guidance

(In thousands, except per share and per share amounts)

(Unaudited)

 

 

 

 

 

 

Q4 2024 Outlook

 

Low

 

High

GAAP diluted net income per share

$

0.10

 

$

0.18

Add back:

 

 

 

Stock-based compensation expense

 

0.15

 

 

0.15

Amortization expense

 

0.03

 

 

0.03

Unrealized (gain) loss on foreign currency

 

0.00

 

 

0.00

Total adjustments

 

0.18

 

 

0.18

Non-GAAP diluted net income per share

$

0.28

 

$

0.36

 

 

 

 

 



Contact:

Investor Relations Contacts:
Protolabs
Ryan Johnsrud, 612-225-4873
Manager – Investor Relations and FP&A
ryan.johnsrud@protolabs.com

Gateway Group, Inc.
949-574-3860
PRLB@gateway-grp.com

Media Contact:
Protolabs
Brent Renneke, 763-479-7704
Marketing Communications Manager
brent.renneke@protolabs.com